Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of dacomitinib and osimertinib, at increasing
doses, to find out what effects, if any, this combination of drugs has on people with
metastatic EGFR mutant lung cancer that has not been treated with an EGFR TKI.